- Value of Positron Emission Tomography of the Para-Aortic Lymph Nodes in Cervical Carcinoma Stage IB2-IIIB
[作者:Vergote, I; Tsolakidis, D; Mortier, D; Neven, P; Amant, F; Mottaghy, F; Van Limbergen, E,期刊:Journal of clinical oncology, 页码:5654-U186 , 文章类型: Letter,,卷期:2008年26-34]
-
- Value of Positron Emission Tomography of the Para-Aortic Lymph Nodes in Cervical Carcinoma Stage IB2-IIIB Reply
[作者:Morice, P; Bentivegna, E; Uzan, C; Gouy, S; Schlumberger, M; Duvillard, P; Haie-Meder, C,期刊:Journal of clinical oncology, 页码:5655-U189 , 文章类型: Letter,,卷期:2008年26-34]
-
- Nonpharmacologic Strategies for Managing Common Chemotherapy Adverse Effects: A Systematic Review
[作者:Lotfi-Jam, K; Carey, M; Jefford, M; Schofield, P; Charleson, C; Aranda, S,期刊:Journal of clinical oncology, 页码:5618-5629 , 文章类型: Review,,卷期:2008年26-34]
- PurposeAdverse effects of chemotherapy can be severe and can have a significant impact on a person's quality of life. With chemotherapy treatment increasingly administered in the ambulatory setting, there is a need for p...
- EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan
[作者:Takano, T; Fukui, T; Ohe, Y; Tsuta, K; Yamamoto, S; Nokihara, H; Yamamoto, N; Sekine, I; Kunitoh, H; Furuta, K; Tamura, T,期刊:Journal of clinical oncology, 页码:5589-5595 , 文章类型: Article,,卷期:2008年26-34]
- Purpose This study evaluated whether the presence of epidermal growth factor receptor (EGFR) mutations is a predictive marker for survival benefit from gefitinib and/or a prognostic marker in patients with advanced lung ...
- Circulating 25-Hydroxyvitamin D, VDR Polymorphisms, and Survival in Advanced Non-Small-Cell Lung Cancer
[作者:Heist, RS; Zhou, W; Wang, ZX; Liu, G; Neuberg, D; Su, L; Asomaning, K; Hollis, BW; Lynch, TJ; Wain, JC; Giovannucci, E; Christiani, DC,期刊:Journal of clinical oncology, 页码:5596-5602 , 文章类型: Article,,卷期:2008年26-34]
- PurposeWe showed previously that in early-stage non-small-cell lung cancer (NSCLC), serum vitamin D levels and VDR polymorphisms were associated with survival. We hypothesized that vitamin D levels and VDR polymorphisms ...
- Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
[作者:Brown, PD; Krishnan, S; Sarkaria, JN; Wu, W; Jaeckle, KA; Uhm, JH; Geoffroy, FJ; Arusell, R; Kitange, G; Jenkins, RB; Kugler, JW; Morton, RF; Rowland, KM; Mischel, P; Yong, WH; Scheithauer, BW; Schiff, D; Giannini, C; Buckner, JC,期刊:Journal of clinical oncology, 页码:5603-5609 , 文章类型: Article,,卷期:2008年26-34]
- PurposeEpidermal growth factor receptor ( EGFR) amplification in glioblastoma multiforme (GBM) is a common occurrence and is associated with treatment resistance. Erlotinib, a selective EGFR inhibitor, was combined with ...
- Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
[作者:Reardon, DA; Fink, KL; Mikkelsen, T; Cloughesy, TF; O'Neill, A; Plotkin, S; Glantz, M; Ravin, P; Raizer, JJ; Rich, KM; Schiff, D; Shapiro, WR; Burdette-Radoux, S; Dropcho, EJ; Wittemer, SM; Nippgen, J; Picard, M; Nabors, LB,期刊:Journal of clinical oncology, 页码:5610-5617 , 文章类型: Article,,卷期:2008年26-34]
- PurposeCilengitide, an inhibitor of alpha v beta 3 and alpha v beta 5 integrin receptors, demonstrated minimal toxicity and durable activity across a wide range of doses administered to adults with recurrent glioblastoma...
- A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer Biomarkers
[作者:Camp, RL; Neumeister, V; Rimm, DL,期刊:Journal of clinical oncology, 页码:5630-5637 , 文章类型: Article,,卷期:2008年26-34]
- This year, 2008, marks the 10-year anniversary of the development of the modern tissue microarray (TMA). During the last decade, the use of TMAs has grown steadily and accounts for a small but increasing percentage of al...
- Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors
[作者:Mross, K; Frost, A; Steinbild, S; Hedbom, S; Rentschler, J; Kaiser, R; Rouyrre, N; Trommeshauser, D; Hoesl, CE; Munzert, G,期刊:Journal of clinical oncology, 页码:5511-5517 , 文章类型: Article,,卷期:2008年26-34]
- PurposeBI 2536 is a novel, potent, and highly specific inhibitor of polo-like kinase 1 (Plk1), which has an essential role in the regulation of mitotic progression. The aim of this trial was to identify the maximum toler...
- Randomized Trial of Postoperative Reirradiation Combined With Chemotherapy After Salvage Surgery Compared With Salvage Surgery Alone in Head and Neck Carcinoma
[作者:Janot, F; de Raucourt, D; Benhamou, E; Ferron, C; Dolivet, G; Bensadoun, RJ; Hamoir, M; Gery, B; Julieron, M; Castaing, M; Bardet, E; Gregoire, V; Bourhis, J,期刊:Journal of clinical oncology, 页码:5518-5523 , 文章类型: Article,,卷期:2008年26-34]
- PurposeFull-dose reirradiation combined with chemotherapy has been shown to be feasible after salvage surgery with acceptable toxicity. The Groupe d'Etude des Tumeurs de la Tete et du Cou and Groupe d'Oncologie Radiother...
- Clinical Outcome and Predictors of Survival in Late Relapse of Germ Cell Tumor
[作者:Sharp, DS; Carver, BS; Eggener, SE; Kondagunta, GV; Motzer, RJ; Bosl, GJ; Sheinfeld, J,期刊:Journal of clinical oncology, 页码:5524-5529 , 文章类型: Article,,卷期:2008年26-34]
- PurposeLate relapse (LR) of germ cell tumor (GCT) is a well recognized entity associated with poor survival. We report on our experience with LR and determine predictors of survival.Patients and MethodsFrom 1990 to 2004,...
|